Urinary tract infection therapeutic refers to various drug treatments used for curing infections in the urinary tract. Antibiotics represent the most common therapeutic class used to effectively cure both uncomplicated and complicated urinary tract infections. With rising prevalence of antibiotic-resistant bacterial strains, there is a growing need for development of alternative and more effective therapies.
The global Urinary Tract Infection Therapeutic Market is estimated to be valued at US$ 8,665.5 Mn in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The growing prevalence of antibiotic resistance presents a major opportunity for development of alternative therapeutics like monoclonal antibodies, vaccines and probiotics to effectively treat urinary tract infections. With rising cases of drug resistance seen in common pathogens like E. coli and K. pneumoniae, there is increased focus on research and development of novel drug classes that can overcome this growing resistance. This ongoing shift towards development of more effective and alternative therapies compared to conventional antibiotics is expected to drive significant growth of the urinary tract infection therapeutic market over the forecast period.
Porter's Analysis
Threat of new entrants: The urinary tract infection therapeutic market requires substantial RD investments and regulatory approvals which pose a high barrier for new players.
Bargaining power of buyers: The bargaining power of buyers is moderate since there are multiple treatment options available.
Bargaining power of suppliers: Major suppliers in this market include drug manufacturers who have specialized expertise. Their differentiated products provide them bargaining power over buyers.
Threat of new substitutes: Alternate treatment options exist but newer drug delivery mechanisms and product innovation help reduce threat from substitutes.
Competitive rivalry: The market comprises large multinational companies investing in RD for novel drugs intensifying competition.
SWOT Analysis
Strength: Established drug brands, extensive RD pipelines and financial resources allow large players to continuously innovate and expand indications.
Weakness: High capital requirements and regulatory complexity hinder small companies from commercializing new drugs. Changing reimbursement policies impact profitability.
Opportunity: Rising prevalence of urinary tract infections globally due to growing elderly population and hospital acquired infections present opportunities.
Threats: Patent expiries of blockbuster brands leads to decline in sales of major players. Emergence of generic competition reduces prices and margins.
Key Takeaways
The global urinary tract infection therapeutic market is expected to witness high growth over the forecast period.
In 2023, North America is estimated to dominate the market due to higher diagnosis rates and accessibility to advanced therapies. The regional market is projected to grow at a CAGR of around 2.5% during 2023-2030. Europe is anticipated to be the second largest urinary tract infection therapeutic market owing to supportive regulatory environment and availability of favorable reimbursement schemes for branded drugs in major countries. With rising public awareness and government initiatives, countries like India, China and Brazil are expected to offer high potential for market growth over the coming years.
Key players operating in the urinary tract infection therapeutic market are Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi Co. Ltd., and GlaxoSmithKline PLC, among others. Pfizer leads with its portfolio of antibacterial drugs for acute and recurrent infections. Shionogi’s research on novel drug classes to overcome antibiotic resistance will be key to expanding treatment options.
